CTOs on the Move

Omega Therapeutics

www.omegatherapeutics.com

 
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

CepTor Corporation

CepTor Corporation is a Cockeysville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MAIA Biotechnology

MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs

Paragon Bioservices

Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon`s aim is to build strong client partnerships with the world`s best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.

Viridian Therapeutics

Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.

Keros Therapeutics

Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases